SWAV Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.95%, SMA50 2.97%, SMA200 39.16%). The stock’s 14-day RSI is 77.63 (overbought), while the ATR of 1.53 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -0.04% below its high and over 113.22% above its low.

Wall Street analysts project EPS growth of 25.0% annually over the next five years. The latest quarter delivered EPS of $1.44. The next quarter is forecast at $1.16. Next year's EPS is expected at $24.52. ShockWave Medical, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 06, 2024, missed forecasts by 38.46%. The prior quarter beat by 26.09%. Over the last six quarters, Apple has recorded several small beats. These include 16.83% in February 16, 2023.

ShockWave Medical, Inc. has 37.54 million shares outstanding. The public float is 37.48 million shares, elevated short interest at 5.50% of float. This equals 1.83 million shares. The short ratio is 2.24 days. Institutional investors hold 99.92% of the float. Insiders own 1.2%. MOLL FREDERIC H holds 287.52 thousand shares, Godshall Douglas Evan has 162.76 thousand shares and Zacharias Isaac has 56.82 thousand shares.

Our AI price prediction model suggests that ShockWave Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.78%, with price expected at $340.72 by June 13, 2024, within a range of $339.38 to $342.10 3-Month Outlook: Projected fall of -13.79%, reaching $288.60 by August 28, 2024, with a range of $272.94 to $303.94. 1-Year Outlook: Projected gain of 22.33%, with price at $409.50 by May 30, 2025, within a range of $393.47 to $427.24.

ShockWave Medical, Inc. (NASDAQ:SWAV) shares are up 75.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ShockWave Medical, Inc. trading at a premium to the broader market with a P/E of 83.43. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $210.33, suggesting -37.17% downside. Our AI forecast model points to short-term strength (1.78% over two weeks), a medium-term fall (-13.79% over three months), and a longer-term gain (22.33% over one year), with expected trading ranges indicating moderate volatility.

ShockWave Medical, Inc. (NASDAQ:SWAV) closed at $334.75 USD, losing -$0.08 (-0.02%) from the previous close of $334.83. The stock is currently trading near its 52-week high $157.00 and $334.90. With a market capitalization of about $12.57 billion, ShockWave Medical, Inc. is classified as a large-cap and shows market-like volatility (beta ~0.88). Key stats such as the average daily volume over the past year has been around 1.25 million shares, trading with heavier-than-usual volume. Headquartered in Santa Clara, CA, ShockWave Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Douglas E. Godshall, the company employs approximately 1,468 people and listed since March 07, 2019. ShockWave Medical, Inc. is a medical technology firm that specializes in the development and global commercialization of intravascular lithotripsy (IVL) systems.

ShockWave Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$231.43. This means the shares are trading below this model’s fair value.

ShockWave Medical, Inc. trades at a P/E ratio of 83.43, slightly above the S&P 500 average, with a price-to-sales ratio of 17.21 and a price-to-book ratio of 18.38 reflecting a rich premium to book value. The P/FCF stands at 75.96, also above market averages. Compared to sector medians, ShockWave Medical, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.